|
... its partnerships, the timing of clinical trial results, including the Phase 2 confirmation trial expected to begin by the end of 2022, the ongoing development of NVX - CoV2373, NanoFlu, its COVID - ...
Adnkronos
-
20-4-2022
|
|
|
|
About the NVX - CoV2373 Phase 3 trials NVX - CoV2373 is being evaluated in two pivotal Phase 3 trials. PREVENT - 19, a trial in the U. S. and Mexico that enrolled almost 30,000 participants aged 18 ...
Adnkronos
-
19-4-2022
|
|
|
|
... Influenza and RSV April 26, 2022 11:00 - 12:00 CET Áñez, G Safety, efficacy and effectiveness of a SARS - CoV - 2 adjuvanted recombinant spike protein vaccine (NVX - CoV2373) in a phase III ...
Adnkronos
-
18-4-2022
|
|
|
|
NVX - CoV2373 is being evaluated in two pivotal Phase 3 trials. PREVENT - 19, a trial in the U. S. and Mexico that enrolled almost 30,000 participants aged 18 years and older, achieved 90.4% efficacy ...
Adnkronos
-
31-3-2022
|
|
|
|
About the NVX - CoV2373 Phase 3 trialsNVX - CoV2373 is being evaluated in two pivotal Phase 3 trials. PREVENT - 19, a trial in the U. S. and Mexico that enrolled almost 30,000 participants aged 18 ...
Adnkronos
-
23-3-2022
|
|
|
|
In addition to its COVID - 19 vaccine, Novavax is also currently evaluating a COVID - seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX - CoV2373 and NanoFlu, ...
Adnkronos
-
10-3-2022
|
|
|
|
In addition to its COVID - 19 vaccine, Novavax is also currently evaluating a COVID - seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX - CoV2373 and NanoFlu, ...
Adnkronos
-
1-3-2022
|
|
|
|
In addition to its COVID - 19 vaccine, Novavax is also currently evaluating a COVID - seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX - CoV2373 and NanoFlu, ...
Adnkronos
-
23-2-2022
|
|
|
|
About the NVX - CoV2373 Phase 3 trialsNVX - CoV2373 is being evaluated in two pivotal Phase 3 trials. PREVENT - 19, a trial in the U. S. and Mexico that enrolled almost 30,000 participants aged 18 ...
Padova News
-
11-2-2022
|
|
|
|
About the NVX - CoV2373 Phase 3 trialsNVX - CoV2373 is being evaluated in two pivotal Phase 3 trials. PREVENT - 19, a trial in the U. S. and Mexico that enrolled almost 30,000 participants, achieved ...
Adnkronos
-
3-2-2022
|
|
|